Jacobs Levy Equity Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Jacobs Levy Equity Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-175,122	Closed	-$3.41M	–	1025
2022 Q4	$3.41M	Sell	175,122 -20,397	-10%	-$403K	0.02%	461
2022 Q3	$4.11M	Buy	195,519 +175,282	+866%	+$4.22M	0.03%	432
2022 Q2	$394K	Sell	20,237 -18,644	-48%	-$440K	﹤0.01%	898
2022 Q1	$856K	Sell	38,881 -263,677	-87%	-$5.38M	0.01%	781
2021 Q4	$4.83M	Buy	302,558 +138,156	+84%	+$2.15M	0.03%	436
2021 Q3	$3.27M	Buy	164,402 +91,669	+126%	+$1.49M	0.02%	520
2021 Q2	$1.26M	Buy	72,733 +49,394	+212%	+$885K	0.01%	700
2021 Q1	$463K	Buy	+23,339	New	+$447K	﹤0.01%	868

Other funds holding MIRM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management's MIRM Position: Q1 2023 in Review

Jacobs Levy Equity Management sold out of Mirum Pharmaceuticals (MIRM) in Q1 2023, closing a stake of 175,122 shares — an estimated $3.41M sold.

Jacobs Levy Equity Management first reported a position in MIRM in Q1 2021 and held it in 8 quarters. The position peaked at $4.83M in Q4 2021. 117 funds tracked by Wall St. Rank hold MIRM as of Q1 2023.

Jacobs Levy Equity Management reported no remaining Mirum Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Jacobs Levy Equity Management sold 175,122 Mirum Pharmaceuticals shares in Q1 2023, an estimated $3.41M.
Jacobs Levy Equity Management first reported a position in Mirum Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Jacobs Levy Equity Management's Mirum Pharmaceuticals position peaked at $4.83M in Q4 2021.
117 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2023, filed 15 May 2023.